Exchange: NASDAQ·Updated 07:00 AM EDT
SGMT logo

SGMT Sagimet Biosciences Inc

$9.14
$0.00
(0.00%)
Pre-Market
Prev Close $9.14
EarningsNov 12
Mkt Cap$562.94M
Vol1,129.00

About SGMT

Sagimet Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapeutics for the treatment of infectious diseases. Its lead drug candidate, denifanstat, is an oral, once-daily pill and selective fatty acid synthase (FASN) inhibitor in development for the treatment of nonalcoholic steatohepatitis (NASH). The company was founded by Urs F. Greber, Ari Helenius, and Lucas Pelkmans on December 19, 2006 and is headquartered in San Mateo, CA.
74

Bullish Sentiment

How do you feel about SGMT?

Advertisement|Remove ads.